In 2017 we celebrate the 40th anniversary of percutaneous coronary intervention (PCI), first performed by Andreas Gruentzig on 16 September 1977. Recognizing the limitations of percutaneous transluminal coronary balloon angioplasty (PTCA), including high rates of acute closure and restenosis, Gruentzig initially believed his technique was best reserved for patients with single-vessel coronary artery disease (CAD). Yet a number of pioneers expanded the use of PTCA to complex CAD, forecasting its superiority to coronary artery bypass graft (CABG) surgery in multivessel disease (MVD). 1 However, early randomized trials demonstrated suboptimal outcomes of PTCA compared with CABG, especially in diabetic patients with MVD. 2 These differences have narrowed in the last two decades, first with the introduction of bare metal stents, then with drug-eluting stents (DES).
The most renowned study to probe the boundaries of PCI is the SYNTAX trial, in which 1800 patients with three-vessel or left main (LM) CAD were randomized between 2005 and 2007 to CABG vs. PCI with first-generation paclitaxel-eluting stents (PES).
3 Surprisingly, LM patients had relatively better outcomes with PCI than those with three-vessel disease. In the latter subgroup (n = 1095), the primary endpoint of major adverse cardiac and cerebrovascular events [MACCE; death, myocardial infarction (MI), stroke, or revascularization] at 1 year occurred in 19.2% vs. 11.5% of patients after PCI vs. CABG, respectively (P < 0.001), 3 and in 37.5% vs. 24.2%, respectively (P < 0.001), at 5 years. 4 Thus, CABG remained the preferred revascularization modality for most patients with complex MVD. One of the greatest legacies of the SYNTAX trial is the creation of the anatomic SYNTAX score (SS). Three-vessel disease patients with low CAD complexity (SS < _ 22) in SYNTAX had similar 5-year MACCE rates with PCI and CABG, whereas those with intermediate or high CAD complexity (SS > _ 23) had superior outcomes with surgery. 4 Notwithstanding issues in reproducibility and training, 5 the SS has stood the test of time and has been incorporated into EU and US guidelines. The SYNTAX score II (SSII) was subsequently developed to discriminate further the outcomes of PCI vs. CABG by adding clinical variables to the anatomic SS. As elegantly described, the SSII identifies some patients with a low SS for whom CABG might be preferred, and others with a higher SS in whom PCI might be preferred, at least as regards prediction of 4-year mortality. However, after applying the SSII in the SYNTAX trial, equipoise was still present in 59% of threevessel disease patients in whom 4-year mortality could not be projected to differ between PCI and CABG with 95% certainty. In the decade since the SYNTAX trial, PCI has substantially evolved ( Figure 1 ). The introduction of second-generation DES has markedly improved both the safety and efficacy of PCI, especially by reducing stent thrombosis, 7 which was responsible for a substantial proportion of adverse events after PES in SYNTAX. 8 Randomized trials have demonstrated that physiological lesion assessment can identify non-flowlimiting lesions which do not require intervention, thereby reducing stent use and MACCE. Stent optimization with intravascular ultrasound (IVUS) imaging guidance improves event-free survival, even with DES. Specialized techniques and devices to recanalize chronic total occlusions (CTOs) allow experts to achieve 90% success rates. The potent P2Y12 platelet receptor antagonists prasugrel, ticagrelor, and cangrelor reduce MI and stent thrombosis after PCI in acute coronary syndromes. Bleeding avoidance strategies, including radial artery intervention and bivalirudin, have become increasingly utilized. A large-scale network meta-analysis has suggested that PCI in the contemporary DES era may have eliminated the incremental advantage of CABG over PCI in reducing death and MI compared with medical therapy alone in stable CAD. 9 Finally, the fundamental importance of optimal medical therapy after revascularization has also been increasingly emphasized, and may have an even greater impact on survival than choice of revascularization modality. 10 To quantify the impact of these PCI enhancements, the SYNTAX II investigators performed PCI in 454 patients at 22 centres with three-vessel disease in whom the SSII predicted equipoise between PCI and CABG. 11 Outcomes were compared with 315 PCI and 334
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• SYNTAX scores. It is also striking that only 7% of patients were female, and that the study population mean left ventricular ejection fraction (LVEF) was 58%. As the SSII suggested that women, patients with left ventricular dysfunction, and those with high SYNTAX scores might have greater survival with CABG than PCI (all other factors being equal), 6 the present results do not apply to these important subgroups. Indeed, SYNTAX II only provides evidence that PCI outcomes are improving in patients who might otherwise have reasonably undergone PCI after the SYNTAX trial. Whether these improved results also apply to higher risk patients without SSII equipoise is uncertain. Thirdly, the extent to which each of the specific PCI advancements utilized in the SYNTAX II strategy contributed to the observed improvement in event-free survival is impossible to determine. This is relevant, for example, as the worldwide penetration of iFR/FFR and intravascular imaging for PCI guidance is substantially less than practised in SYNTAX II, questioning the generalizability of the SYNTAX II results to the 'real-world'. Conversely, even better PCI outcomes than observed in SYNTAX II may be obtained by routinely performing pre-PCI intravascular imaging (in addition to post-PCI imaging), by assessing angiographically non-obstructive lesions for physiological significance (and/or performing post-PCI iFR or FFR), by careful patient selection and expert technique to achieve complete revascularization (the rate of which was not reported in SYNTAX II, but is essential to optimize event-free survival after PCI), 12 and by even greater utilization of guideline-directed medical therapy during follow-up. 10 Fourthly, and perhaps most importantly, SYNTAX II follow-up has only been completed through 1 year. In almost all randomized trials, the benefits of CABG compared with PCI have progressively emerged over time. Indeed, among patients with three-vessel disease in the SYNTAX trial, the composite endpoint of death, MI, or stroke (a more important outcome measure than MACCE) was similar after PCI and CABG at 1 year, 3 but substantially worse after PCI at 5 years. 4 In this regard, a prematurely terminated randomized trial in 880 MVD patients found no significant difference between PCI with a second-generation DES and CABG at 5 years for the composite rate of death, MI, or stroke (although the confidence interval around the point estimate was wide, and MACCE were still reduced with CABG). 13 Lastly, CABG outcomes continue to improve, with increasing utilization of pan-arterial revascularization, minimally invasive and robotic techniques; greater use of carotid, aortic, and left ventricular ultrasound screening, and 'no-touch' techniques to reduce periprocedural stroke; and optimization of in-hospital and long-term pharmacotherapy. The EXCEL trial, in which contemporary best practices for PCI and CABG were employed, recently demonstrated a nearly identical 3-year hazard of death, MI, or stroke with PCI using a second-generation DES vs. CABG in 1905 patients with LM CAD and low or intermediate SS, 51% of whom had concomitant MVD. 14 As in SYNTAX II, outcomes in EXCEL were independent of SS and diabetes. However, while the 30-day outcomes were superior with PCI, more events in the PCI arm accrued thereafter, further emphasizing the importance of long-term follow-up.
Thus, although the SYNTAX II study enticingly suggests an increasing role for PCI in MVD, confirmatory evidence from adequately powered randomized trials is required prior to expanding the zone of equipoise to include most patients with complex CAD. The ongoing randomized FAME 3 trial (NCT02100722), in which 1500 MVD patients are being randomized to FFR-guided PCI of flowlimiting lesions with contemporary DES vs. CABG will provide important insight as to whether contemporary PCI is ready to declare 'game, set, and match'.
